目的 观察血小板衍生生长因子-C(platelet-derived growth factor-C,PDGF-C)对体外培养的人卵巢透明细胞癌(ovarian clear cell carcinoma,OCCC)ES-2细胞的增殖和趋化作用。方法 体外培养ES-2细胞,添加不同浓度的PDGF-C进行干预,应用CCK8试剂盒法评价细胞增殖情况,流式细胞术检测细胞周期,利用Transwell细胞迁移实验、细胞划痕实验测定细胞迁移能力。结果 与未加PDGF-C的对照组相比,PDGF-C能明显刺激ES-2细胞的增殖,在第4天增殖达高峰,PDGF-C促增殖最佳作用浓度是20 μg/L;经不同浓度PDGF-C的刺激,处于细胞周期G1期的ES-2细胞比例较对照组明显降低(P<0.05),处于S期的ES-2细胞比例显著升高(P<0.05),而处于G2+M期的细胞比例则无明显变化(P＞0.05)。同时,PDGF-C提高了ES-2细胞的迁移能力。结论 PDGF-C可促进体外培养的ES-2细胞的增殖、迁移能力。
Abstract
Objective To examine the effect of platelet-derived growth factor-C (PDGF-C) on ovarian clear cell carcinoma cells ES-2 in vitro.Methods ES-2 cells were cultured with the supplement of different concentrations of PDGF-C (0, 10, 20 and 40 μg/L). CCK8 assay was used to detect the effect of PDGF-C on cell proliferation. Flow cytometry was used to detect cell cycle phases. Transwell assay and cell scratch test were used to detect cell migration ability.Results PDGF-C could not only significantly induce proliferation of ES-2 compared with the blank control group without PDGF-C, but increase the percentage of the cells in S phase. Additionally, it was found the best concentration of PDGF-C to promote the proliferation of ES-2 cells was 20 μg/L. With the stimulation of different concentrations of PDGF-C, the proportion of ES-2 cells in G1 and S cell cycle was significantly decreased (P<0.05) and significantly increased (P<0.05) respectively, while the proportion of cells in G2 + M phase did not change compared with the control group (P>0.05). At the same time, PDGF-C increased the migration ability of ES-2 cells.Conclusions PDGF-C can promote the proliferation and migration of ES-2 cells in vitro.
关键词
血小板衍生生长因子C /
ES-2细胞系 /
细胞增殖 /
趋化作用
Key words
platelet-derived growth factor-C /
ES-2 /
cell proliferation /
cell migration
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Rooth C. Ovarian cancer: risk factors,treatment and management [J]. Br J Nurs,2013,22 (17) : S23-30.
[2] Collins Y, Holcomb K,Chapman-Davis E,et al. Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology [J]. Gynecol Oncol,2014,133(2):353-361.
[3] Lee Y Y, Kim T J, Kim M J, et al.Prognosis of ovarian clear cell carcinoma compared toother histological subtypes: a meta-analysis [J]. Gynecol Oncol, 2011, 122(3): 541-547.
[4] SugiyamaT, KamuraT, Kigawa N, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy [J]. Cancer, 2000, 88: 2584-2589.
[5] Lai K K, Shang S, Lohia N, et al. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models [J]. PLoS Genet, 2011, 7(6): e1002147.
[6] Khajah M A, Al S S, Mathew P M, et al. Differential effect of growth factors on invasion and proliferation of endocrine resistant breast cancer cells[J]. PLoS One, 2012, 7(7):e41847.
[7] Ruffini F, Tentori L, Dorio A S, et al. Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness [J]. Oncol Rep, 2013, 30(6):2887-2896.
[8] Vera C,Tapia V,Vega M,et al.Role of nerve growth factor and its TRKA receptor in normal ovarian and epithelial ovarian cancer angio genesis [J]. J Ovarian Res,2014, 7: 82.
[9] McCormack D R,Walsh A J,Sit W,et al. In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts [J]. Biomed Opt Express,2014, 5(7) : 2247-2261.
[10] Neto J S, Kho R M, Siufi D F D S, et al. Cellular, Histologic, and Molecular Changes Associated With Endometriosis and Ovarian Cancer [J]. Journal of Minimally Invasive Gynecology, 2014, 21(1): 55~63.
[11] Sun Y. Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures [J]. Med Res Rev, 2015, 35(2):408-436.
[12] Frings O, Augsten M, Tobin N P, et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling [J]. Am J Pathol, 2013, 182(6): 2037-2047.
[13] Uutela M, Lauren J, Bergsten E, et al. Chromosomal location, exon structure, and vascular expression patterns of the human PDGF-C and PDGF-D genes [J]. Circulation, 2001, 103(18): 2242-2247.
[14] Savikko J, Teppo A M, Taskinen E, et al. Different effects of tacrolimus and cyclosporine on PDGF induction and chronic allograft injury: evidence for improved kidney graft outcome [J]. Transpl Immunol, 2014, 31(3): 145-151.
[15] Demaria M, Ohtani N, Youssef S A, et al. An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA [J]. Dev Cell, 2014, 31(6): 722-733.
[16] Guo J, Li L, Wu Y J, et al. Inhibitory effects of Brazilin on the vascular smooth muscle cell proliferation and migration induced by PDGF-BB [J]. Am J Chin Med, 2013, 41(6): 1283-1296.
[17] Bonner J C. Regulation of PDGF and its receptors in fibrotic diseases [J]. Cytokine Growth Factor Rev, 2004, 15(4): 255-273.
[18] Martin I V, Borkham-Kamphorst E, Zok S, et al. Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis [J]. Am J Pathol, 2013, 182(1): 107-117.
[19] Grun K, Markova B, Bohmer F D, et al. Elevated expression of PDGF-C in coxsackievirus B3-induced chronic myocarditis [J]. Eur Heart J, 2005, 26(7): 728-739.
[20] Li R, Maminishkis A, Wang F E, et al. PDGF-C and -D induced proliferation/migration of human RPE is abolished by inflammatory cytokines [J]. Invest Ophthalmol Vis Sci, 2007, 48(12): 5722-5732.
[21] Campbell J S, Hughes S D, Gilbertson D G, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma [J]. Proc Natl Acad Sci USA, 2005, 102(9): 3389-3394.
PDF(6169 KB)
